AR and Familial prostate cancer: Consistent with these results, survivin (BIRC5) expression varied significantly across prostate cancer subtypes (ANOVA p = 0.049) among previously profiled preclinical models [35] by ATAC-seq, with higher levels observed in AR-low/AR-negative subtypes, including small-cell-like (SCL), WNT-driven, and NEPC tumors, compared to AR-positive tumors (AR+) (Figure 1F).